Literature DB >> 7538255

Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17.

C M Pierce1, P V Rossitto, N J MacLachlan.   

Abstract

Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17 (BTV-17) were investigated with a panel of five neutralizing monoclonal antibodies (MAbs). One MAb (MAb 034) was originally raised to BTV serotype 10 (BTV-10) but also neutralizes BTV-17 (P. V. Rossitto, and N. J. MacLachlan, 1992, J. Gen. Virol. 73, 1947-1952). Competitive binding studies indicate that the MAbs recognize at least two epitopes on the neutralizing outer capsid protein VP2 of BTV-17. The MAbs were used to select neutralization-resistant variant [escape mutant (EM)] viruses and to determine the phenotypic characteristics of these EM viruses by immunoprecipitation and neutralization assays. Sequencing of the L2 gene, which encodes VP2, identified mutations responsible for the altered phenotypic properties exhibited by each EM virus. Four amino acids in three regions of VP2 are critical to the expression of the epitopes recognized by the panel of neutralizing MAbs. Amino acid 199 affects the binding of MAbs 17.82, 17.83, and 17.813; amino acid 213 affects the binding of MAb 17.85; and amino acids 327 and 582 synergistically affect the binding of MAb 034. Similarly, amino acids 327 and 402 synergistically affect the binding of MAb 034 to BTV-10 (C. D. DeMaula, H. W. Heidner, P. V. Rossitto, C. M. Pierce, and N. J. MacLachlan, 1993, Virology 195, 292-296), suggesting that the neutralizing epitope common to BTV-10 and BTV-17 has a similar location in VP2 of these two antigenically distinct viruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538255     DOI: 10.1006/viro.1995.1253

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.

Authors:  René G P van Gennip; Sandra G P van de Water; Christiaan A Potgieter; Piet A van Rijn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Bluetongue virus outer capsid protein VP5 interacts with membrane lipid rafts via a SNARE domain.

Authors:  Bishnupriya Bhattacharya; Polly Roy
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

3.  Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2.

Authors:  Narender S Maan; Sushila Maan; Manjunatha N Belaganahalli; Eileen N Ostlund; Donna J Johnson; Kyriaki Nomikou; Peter P C Mertens
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

4.  Animal viral diseases and global change: bluetongue and West Nile fever as paradigms.

Authors:  Miguel Á Jiménez-Clavero
Journal:  Front Genet       Date:  2012-06-13       Impact factor: 4.599

5.  Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress.

Authors:  Bishnupriya Bhattacharya; Rob J Noad; Polly Roy
Journal:  Virol J       Date:  2007-01-15       Impact factor: 4.099

6.  A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.

Authors:  Sandro Filipe Nunes; Claude Hamers; Maxime Ratinier; Andrew Shaw; Sylvie Brunet; Pascal Hudelet; Massimo Palmarini
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

7.  Development of plant-produced protein body vaccine candidates for bluetongue virus.

Authors:  Albertha R van Zyl; Ann E Meyers; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2017-05-30       Impact factor: 2.563

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.